AMENDMENTS TO THE SPECIFICATION

Please replace the paragraph beginning at page 8, line 17, with the following paragraph:

As used herein, "sequence identity" with respect to a reference peptide can be computed by using the BLASTP and TBLASTN programs which employ the BLAST (basic local alignment search tool) 2.0.14 algorithm; BLASTP and 20 TBLASTN settings to be used in such computations are indicated in Table 1 below. Amino acid sequence identity is reported under "Identities" by the BLASTP and TBLASTN programs. Techniques for computing amino acid sequence identity are well known to those skilled in the art, and the use of the BLAST algorithm is described in Altschul et al. (1990), *J. Mol. Biol.* 215: 403-10 and Altschul et al. (1997), *Nucleic Acids Res.* 25:3389-3402, the disclosures of which are herein incorporated by reference in their entirety. ~~BLASTP and TBLASTN programs utilizing the BLAST 2.0.14 algorithm and can be accessed at http://www.ncbi.nlm.nih.gov/.~~

Replace the paragraph beginning at page 18, line 13, with the following paragraph:

Agnoprotein, or biologically active fragments or derivatives of agnoprotein, can inhibit proliferation of normal and abnormally proliferating cells. Abnormally proliferating cells include cells from cancer types of diverse histologic subtype and origin, such as those listed and described in the National Cancer Institute's "CancerNet," ~~at:~~
——— ~~http://cancernet.nci.nih.gov/pdq/pdq_treatment.shtml~~
——— which is herein incorporated by reference in its entirety.

Replace the paragraph beginning at page 19, line 7, with the following paragraph:

Furthermore, the compounds of the invention can be used to inhibit the proliferation of cells from cancers or tumors in any prognostic stage of development, as measured, for example, by the "Overall Stage Groupings" (also called "Roman Numeral") or the Tumor, Nodes, and Metastases (TNM) staging systems. Appropriate prognostic staging systems and stage descriptions for a given cancer are known in the art, for example as described in[[:]] the National Cancer Institute's "CancerNet," http://cancernet.nci.nih.gov/pdq/pdq_treatment.shtml, supra.